Edition:
United States

Clearside Biomedical Inc (CLSD.OQ)

CLSD.OQ on NASDAQ Stock Exchange Global Market

5.97USD
15 Dec 2017
Change (% chg)

-- (--)
Prev Close
$5.97
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
50,310
52-wk High
$10.46
52-wk Low
$5.44

Chart for

About

Clearside Biomedical, Inc. is a clinical biopharmaceutical company developing first-in-class drug therapies to treat blinding diseases of the eye. The Company's product candidates focus on diseases affecting the retina, which is the tissue that lines the inside of the eye and is primarily responsible for vision, and the choroid,... (more)

Overall

Beta: --
Market Cap(Mil.): $151.29
Shares Outstanding(Mil.): 25.34
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 198.20 16.04
EPS (TTM): -- -- --
ROI: -- -11.76 34.69
ROE: -- -36.72 15.46

BRIEF-Clearside Biomedical Q3 loss per share $0.72

* Clearside Biomedical, Inc. Announces third quarter 2017 financial results and provides corporate update

Nov 08 2017

BRIEF-Clearside Biomedical announces completion of patient enrollment in phase 2 clinical trial of CLS-TA

* Clearside Biomedical announces completion of patient enrollment in phase 2 clinical trial of CLS-TA used together with Eylea in patients with diabetic macular edema

Oct 24 2017

BRIEF-Clearside Biomedical reports Q2 loss per share $0.54

* Announces second quarter 2017 financial results and provides corporate update

Aug 09 2017

BRIEF-Clearside Biomedical completes patient enrollment in Phase 3 Peachtree Clinical Trial of CLS-TA

* Announces completion of patient enrollment in pivotal Phase 3 Peachtree Clinical Trial of CLS-TA for Suprachoroidal administration in patients with Macular Edema associated with non-infectious Uveitis

Aug 07 2017

BRIEF-Clearside Biomedical announces first patient randomized in phase 2 clinical trial of CLS-TA

* Clearside Biomedical announces first patient randomized in phase 2 clinical trial of cls-ta used together with eylea in patients with diabetic macular edema

Jul 11 2017

BRIEF-Clearside Biomedical files for mixed shelf offering of up to $250 mln - SEC Filing‍​ ‍​

* Clearside Biomedical Inc files for mixed shelf offering of up to $250 million - SEC Filing‍​ ‍​ Source text: [http://bit.ly/2tDFDPJ] Further company coverage:

Jul 03 2017

BRIEF-Clearside Biomedical ‍on June 30, entered into sales agreement with Cowen and Company, LLC - SEC Filing​

* Clearside Biomedical Inc - ‍on June 30, 2017, Clearside Biomedical, Inc. entered into sales agreement with Cowen and Company, LLC - SEC Filing​

Jul 03 2017

Earnings vs. Estimates